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Background: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability
progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate
(HR) in the 6 hours after drug intake.
The aim of the study is to to assess safety and tolerability of the first dose of fingolimod in a cohort of Italian patients with
RRMS without alternative therapeutic options.
Methods: Open-label, single arm, multicentre study. After the first dose of fingolimod, patients were observed for 6 hours
and had their vital signs monitored hourly. Extended on-site monitoring was provided when required.
Results: Of the 906 patients enrolled in the study, most (95.2%) did not experience any adverse event (AE) following
fingolimod administration. Cardiovascular AEs occurred in 18 patients and included bradycardia (1.3%), first-and
second-degree atrioventricular block (0.1% and 0.2%), palpitations (0.1%), sinus arrhythmia (0.1%) and ventricular
premature beats (0.1%). All events were self-limiting and did not require any intervention. Extended monitoring
was required in 34 patients.
Conclusions: These results, in a population who better resembled real-world clinical practice in terms of concomitant
diseases and medications, are consistent with previous clinical trials and confirmed that the first dose administration of
fingolimod is generally safe and well tolerated.
Trial registration: EudraCT 2011-000770-60
Keywords: Atrioventricular block, Bradycardia, Multiple sclerosis, Fingolimod, Safety, TolerabilityBackground
Fingolimod (Gilenya™, Novartis) is an oral drug recently
approved in Europe and the USA for the treatment of
relapsing-remitting multiple sclerosis (RRMS). Phase II
and III clinical trials have shown that fingolimod is
superior to placebo and interferon beta-1a in preventing
relapses; it also delays disability progression compared to
placebo [1-3]. The mechanism of action of fingolimod is
based on its functional antagonism of the receptors for
sphingosine-1 phosphate (S1P) expressed by lymphocyte
subpopulations. The binding of S1P to S1P receptors* Correspondence: glmancardi@neurologia.unige.it
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unless otherwise stated.normally mediates the egress of lymphocytes from
lymph nodes, so the binding and internalization of
these receptors by fingolimod blocks this signalling
and results in compartmentalization of circulating
lymphocytes in the peripheral lymphoid organs. This
strongly reduces the attack induced by the circulating
myelin-reactive lymphocytes.
The interaction of fingolimod with S1P receptors in
tissues outside the immune system can lead to side
effects. More specifically, fingolimod is associated with a
transient decrease in heart rate (HR) after the first dose
intake, likely due to its interaction with S1P1 receptors
expressed in atrial myocytes [4]. This transient decline
in HR after the first dose of fingolimod was first ob-
served in a clinical trial with renal transplant patients
[5]. Phase II and phase III clinical trials in MS patientstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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crease in HR within the 6 hours after the first adminis-
tration (with a nadir at the fourth to fifth hour post
dose), which is transient, dose-dependent and usually
asymptomatic, and that first- and second-degree Mobitz
type I atrioventricular block (AVB) may occur as a com-
plication of the treatment [1-3]. A recent pooled analysis
of data from three phase III clinical trials with fingoli-
mod in MS showed that, in the 1212 patients treated
with fingolimod 0.5 mg/day, symptomatic bradycardia
(with dizziness and moderate somnolence) occurred in
0.6% of patients, and the incidence of AVB was 4.7% for
first-degree AVB (versus 1.7% in the placebo group) and
0.2% for second-degree AVB Mobitz type I (versus 0
cases in the placebo group) [6]. In addition, two case re-
ports have been published describing cardiac complica-
tions in patients with MS receiving fingolimod; one
reporting transient asystole lasting for 7.5 seconds oc-
curring 21 hours after the first dose in a subject who
was under treatment with the antipsychotic drug risperi-
done [7], and another reporting endocarditis resulting in
severe mitral regurgitation, atrial fibrillation, and
congestive heart failure in a patient with MS, Leiden V
mutation, psoriasis and sicca syndrome, where fingolimod
was considered a possible contributor to the cardiac
complications [8].
The cardiac safety profile of fingolimod was reviewed
in 2012 by the US Food and Drug Administration (FDA)
and the European Medicines Agency (EMA), prompted
by a report in the post-marketing period of a sudden
death, within the 24 hours following the first dose, of a
patient who suffered from hypertension and was co-
treated with the calcium-channel blocker amlodipine
and the beta-blocker metoprolol [9,10]. The conclusion
of this review was that the overall benefit/risk ratio of
fingolimod is positive, although hourly check of HR
and blood pressure (BP) and electrocardiographic (ECG)
monitoring at the first dose (either continuous, according
to the EMA, or pre-dose and 6 hour post dose, according
to the FDA) is recommended. Also the co-administration
of fingolimod and drugs which can cause bradycardia and
QT prolongation should be avoided [9,10].
In the period when fingolimod had already been ap-
proved by the EMA but was not yet available in the local
market in Italy, a clear ethical and clinical need appeared
evident for all patients considered to be without alterna-
tive therapeutic options. Such patients were those with
an unsatisfactory response or poor tolerability to inter-
feron beta or glatiramer acetate and who developed an
excessive risk of progressive multifocal leukoencephalo-
pathy (PML) in association with natalizumab therapy (or
those who refused to take any PML risk). In order to
meet this important medical need, an open-label single
arm study was initiated in Italy at the beginning of 2011with the two fold objective of providing the above
mentioned patients access to fingolimod and collecting
safety and tolerability data in this population, which is
broader than that of the pivotal trials in terms of con-
comitant diseases and medications received. Here we
report the safety and tolerability results of the first
dose of fingolimod.
Methods
Study design
The clinical trial CFTY720 DIT03 (EudraCT number
2011-000770-60) was a non-comparative, open-label,
multicentre study of the administration of fingolimod
in patients with RRMS for whom no alternative suit-
able therapy was available. All patients provided writ-
ten informed consent. After a screening period of 14
days, all eligible patients started treatment with fingoli-
mod at the baseline visit. Follow up visits to assess tol-
erability and safety were conducted at month 1, month
3, month 6 and then every 6 months, until the end of
the study, which occurred when the market drug was
available at the specific site. Expanded Disability Status
Scale (EDSS) was also scored at baseline and at the end
of the study, and any relapse which might have oc-
curred was recorded. Only the safety and tolerability
data associated with the initial dose of fingolimod are
reported herein.
Patients
Eligibility criteria included relapsing remitting disease
course, age 18 years or older, no other therapy options,
EDSS score of 0 to 6.5 (inclusive), minimum washout
period of 3 months in case of previous treatment with
natalizumab. Key exclusion criteria were history of chronic
disease of the immune system other than MS, infections
(active systemic bacterial, viral or fungal infections), history
or presence of malignancy, uncontrolled diabetes or
moderate to severe diabetic retinopathy, macular oedema,
negative varicella-zoster IgG antibody status, severe cardio-
vascular disease, treatment with class Ia or class III antiar-
rhythmic drugs and uncontrolled arterial hypertension.
First dose administration
After a screening period of about 14 days, during which
patient eligibility was verified through blood tests, vital
signs measurement (HR, systolic and diastolic BP), ECG
recording and ophthalmic evaluation, the first dose of
fingolimod was administered at the baseline visit. Vital
signs were measured again prior to study drug intake.
Patients were then observed for 6 hours after treatment
initiation for signs and symptoms of bradycardia (first dose
monitoring) and by checking HR and BP hourly. Extended
on-site monitoring was required in cases where the patient
had symptomatic bradycardia or the HR at 6 hours was the
Table 1 Baseline demographics and characteristics
Variable n = 906
Age, years
Mean ± SD 39.10 ± 9.87
Median (range) 39 (18–64)
Gender, n (%)
Female 579 (63.9)
Male 327 (36.1)
Age at MS diagnosis, years
Mean ± SD 30.52 ± 9.52
Median (range) 29 (8–60)
Duration of MS, yearsa
Mean ± SD 8.56 ± 5.97
Median (range) 7 (0–31)
Number of relapses in previous year
Mean ± SD 1.36 ± 0.67
Median (range) 1 (1–5)
EDSS score
Mean ± SD 3.06 ± 1.65
Median (range) 3.0 (0–6.5)
Treatment history, n (%)b
Interferon beta-1a or -1b 445 (49.1)
Natalizumab 220 (24.3)
Glatiramer acetate 186 (20.5)
Azathioprine 19 (2.1)
Experimental drugs 7 (0.8)
Other 4 (0.4)
None 25 (2.8)
EDSS Expanded Disability Status Scale; MS multiple sclerosis; SD standard deviation.
aTime from MS diagnosis to enrolment.
bLast MS treatment.
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lution of symptoms or increase in HR, according to the in-
vestigator’s clinical judgement. Patients with symptomatic
bradycardia were required to take the second dose of fingo-
limod at the clinical centre.
Neither ECG pre and post dose, nor continuous ECG
monitoring was mandated by the study protocol; ECG
was performed at discharge or at any time during the 6
hours if clinically indicated and evaluated by a cardiolo-
gist. The study protocol did not include a definition for
bradycardia, which was reported based on the judgment
of the treating neurologist.
Ethical requirements
This clinical study was performed in accordance with
the ICH Harmonized Tripartite Guidelines for Good
Clinical Practice, with applicable local regulations, and
with the ethical principles laid down in the Declaration of
Helsinki. The study was approved by the local Ethics
Committees (Appendix 1). Written informed consent
was obtained for the publication of individual clinical
details.
Statistical analysis
The population of the present analysis is all patients
who received at least one dose of study drug. Since
data were not normally distributed, the nonparametric
Mann-Whitney U test was employed to detect inter-
group differences. Fisher’s exact test was employed to
compare the prevalence of concomitant treatments
among groups. A p-value less than or equal to 0.05 was
considered significant.
Results
Study population: baseline characteristics
In total, 906 patients were enrolled in this trial (CFTY720
DIT03) and included in this analysis. Table 1 shows the
baseline characteristics of patients included in this study.
The mean age of the population was 39 years, and 36%
were male. Patients had a mean duration of MS of 8.56
years and a mean EDSS score of 3.06. Approximately 25%
of patients had previously received natalizumab.
Concomitant medical conditions included hypertension
(34/906 patients; 3.8%), mood disorders (75/906 patients;
8.3%) and headache (31/906 patients; 3.4%). Fifteen per cent
(136/906) of patients were treated at baseline with drugs
which had the potential effect of decreasing HR or prolong-
ing QT interval, as detailed later.
At the baseline assessment, data on BP and HR were
available for 905 patients. Of these, 125 patients (13.8%)
had a systolic BP ≥140 mmHg and/or diastolic BP ≥90
mmHg. Median HR before starting the treatment was 74
beats per minute (bpm) (±10.0) and 39 patients (4.3%)
had a HR lower than 60 bpm.Adverse events during the first dose administration
The majority of patients (863/906; 95.3%) did not have
any adverse event following the first administration. The
remaining 43 patients (4.7%) had at least one adverse
event during the first dose monitoring as reported in
Table 2. Of the non-cardiac symptoms, headache was
the most frequent (6/906; 0.7%), followed by nausea (5/905;
0.6%). Cardiovascular adverse events occurred in 18/906
patients (2.0%) and included bradycardia (12/906; 1.3%),
first-degree AVB (1/906; 0.1%), second-degree AVB Mobitz
type I (2/906; 0.2%), palpitations (1/906; 0.1%), sinus
arrhythmia (1/906; 0.1%) and ventricular premature beats
(1/906; 0.1%). Four out of 12 patients with bradycardia had
symptoms related to HR decrease such as nausea, asthenia
and vertigo. One serious adverse event occurred in one
subject with second-degree AVB Mobitz type 1; although
the patient was asymptomatic and the event spontaneously
resolved, the patient was hospitalized and treatment was
Table 2 Adverse events reported during first dose
monitoring after fingolimod administration
Adverse event, n (%) n = 906
Cardiac disorders 18 (2.0)
Atrioventricular block first degree 1 (0.1)
Atrioventricular block second degree 2 (0.2)
Bradycardia 12 (1.3)
Palpitations 1 (0.1)
Ventricular premature beats 1 (0.1)
Sinus arrhythmia 1 (0.1)
Ear and labyrinth disorders 2 (0.2)
Vertigo 2 (0.2)
Gastrointestinal disorders 8 (0.9)
Diarrhoea 2 (0.2)
Nausea 5 (0.6)
Vomiting 1 (0.1)
General disorders and administration site conditions 7 (0.8)
Asthenia 4 (0.4)
Chest pain 1 (0.1)
Chills 1 (0.1)
Hyperpyrexia 1 (0.1)
Malaise 1 (0.1)
Infections and infestations 3 (0.3)
Influenza 1 (0.1)
Nasopharyngitis 1 (0.1)
Urinary tract infection 1 (0.1)
Musculoskeletal and connective tissue disorders 2 (0.2)
Pain in extremity 2 (0.2)
Nervous system disorders 11 (1.2)
Dysgeusia 1 (0.1)
Headache 6 (0.7)
Paraesthesia 1 (0.1)
Dizziness 1 (0.1)
Neuralgia 1 (0.1)
Somnolence 2 (0.2)
Eye disorders 1 (0.1)
Vision blurred 1 (0.1)
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with persistent bradycardia reported by the treating neur-
ologist, although it was deemed mild (HR 59 bpm). There-
fore, two out of 906 patients permanently discontinued the
treatment due to an adverse event occurring during the first
dose monitoring.
AVB details are provided in Table 3. The three cases of
AVB were detected during the course of the 6 hour
monitoring, since ECG was performed, as clinically indi-
cated. In particular, in one case (Case 1) arrhythmicfrequencies were detected at pulse assessment, while in
another case (Case 2) the investigator observed a large
decrease in HR (15 bpm). In the last case (Case 3) the
patient underwent the ECG due to appearance of symp-
toms (asthenia) probably related to the decrease in HR.
All three patients with AVB had received interferon
treatment prior to fingolimod: patient 1 was treated
with intramuscular interferon beta-1a for 6 months and
started fingolimod after a 1-month washout period; pa-
tient 2 was treated with subcutaneous interferon beta-1a
(22 μg) for 2 years, then with subcutaneous interferon
beta-1a (44 μg) for an additional 2.5 years and started
fingolimod after a 1-month washout period; patient 3
was treated with subcutaneous interferon beta-1a (22 μg)
for 1 month, then with subcutaneous interferon beta-1a
(44 μg) for an additional year and started fingolimod after a
3-month washout period.
Extended monitoring
The majority of patients (867/906; 95.7%) was dis-
charged after six hours and continued fingolimod ther-
apy as outpatients. Extended monitoring was required in
34/906 (3.8%) patients due to: symptomatic bradycardia
(2/906; 0.2%), lowest HR value at the sixth hour post-
administration (28/906; 3.0%), first-degree AVB and symp-
tomatic bradycardia (1/906; 0.1%), second-degree AVB
Mobitz type I (2/906; 0.2%) or high BP (1/906; 0.1%). Five
of these 34 patients also returned on the second day to re-
peat the procedure for the monitoring after dose intake.
Baseline HR was not different in those who underwent ex-
tended monitoring versus those who were discharged at the
sixth hour (mean values of 75.97 vs 73.97 bpm; p = 0. 436).
Baseline systolic BP values were similar in the two groups
(119.53 mmHg for those with extended monitoring vs
118.66 mmHg for those who were discharged at the
sixth hour; p = 0.6380), as well baseline diastolic BP (77.59
mmHg vs 74.76 mmHg; p = 0.0704). Additionally, five
subjects (0.5%) were discharged at the sixth hour with-
out the need of extended monitoring but returned the
next day for clinical evaluation and administration of
the second dose (Figure 1).
Concomitant medications
Table 4 describes the use of concomitant medications with
a potential effect on cardiac function in the overall study
population (906 patients) and in the population who under-
went the extended monitoring (34 patients). No significant
relationship between the concomitant treatment with
beta-blockers, selective serotonin reuptake inhibitors
(SSRI), tricyclic antidepressants, serotonin–norepin-
ephrine reuptake inhibitors (SNRI) antidepressants,
antipsychotic drugs, muscle relaxants, antimuscarinic drugs
or macrolide antibiotics and the need for extended
monitoring was found; while the use of topiramate,
Table 3 Details on the three cases of atrioventricular block (AVB) with onset after the first dose of fingolimod
Gender, age
(case number)
Event CV medical
history
Concomitant
medications
CV baseline
assessment
Onset of event,
hours post dose
HR at onset
(bpm)
Outcome Action
taken
Female, 24 Second degree
AVB, M1
None Topiramate Normal ECG 3 54
(arrhythmic)
Spontaneously
resolved within
12 hours
Patient was
hospitalized
(Case 1) HR: 67 bpm
BP: 100/60
mmHg
Male, 29 Second degree
AVB, M1
Cardiac
murmur
None Abnormal
ECGa
2 58 Spontaneously
resolved within
12 hours
Patient was
hospitalized.
Study drug
discontinued(Case 2) HR: 73 bpm
BP: 130/90
mmHg
Female, 29 First degree AVB None Trazodone Normal ECG 4 68 Spontaneously
resolved the
day after
None
(Case 3) HR: 72 bpm,
BP: 112/75
mmHg
AVB: atrioventricular block, BP: blood pressure, bpm: beats per minute, CV: cardiovascular, ECG: electrocardiogram, HR: heart rate, M1: Mobitz type 1.
aDeemed not clinically significant; slight delay in right AV activation.
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significantly associated with need for extended moni-
toring (p = 0.03, p = 0.01, p = 0.03 respectively), the
patient numbers were small (2/34, 2/34 and 1/34,
respectively). In detail, topiramate was taken by one
patient who developed second-degree AVB and by one
patient who was not discharged due to lowest HR atFigure 1 Patient disposition after first dose of fingolimod administratsixth hour (HR after 6 hours was 65 bpm), while two
patients treated with 4-aminopyridine were not dis-
charged due to lowest HR at sixth hour. Additionally,
the only patient with first-degree AVB was the only
subject treated with the antidepressant drug trazodone
in the whole cohort. Given the small number of sub-
jects, caution is warranted in interpreting these results.ion.
Table 4 Concomitant medications, n (%), in the total patient population (n = 906) and in patients who underwent
extended monitoring after the first dose of fingolimod (n = 34)
Potential CV effect Drug class Drug Total population Patients who underwent extended monitoring P-value*
Bradycardia Antihypertensive Beta-blockers 6 (0.7) 0 NS
Anti-epilepsy, anti-migraine Topiramate 8 (0.9) 2 (0.6) 0.03
Prolong QT interval Anti-fatigue Amantadine 18 (2.0) 1 (0.3) NS
Modafinil 4 (0.4) 0 NS
4-Aminopiridine 5 (0.5) 2 (0.6) 0.01
Antidepressant Tricyclicsa 10 (1.1) 0 NS
SSRIsb 58 (6.4) 1 (0.3) NS
Escitalopram 26 (2.9) 1 (0.3) NS
SNRIsc 35 (3.9) 2 (0.6) NS
Duloxetine 21 (2.3) 2 (0.6) NS
Trazodone 1 (0.1) 1 (0.3) 0.03
Bupropion 2 (0.2) 0 NS
Mirtazapine 3 (0.3) 0 NS
Anti-psychotics 7 (0.8) 0 NS
Muscle relaxants Tizanidine 3 (0.3) 0 NS
Antimuscarinic drugs Tolterodine 2 (0.2) 0 NS
Solifenacin 5 (0.5) 0 NS
Antibiotics Macrolides 1 (0.1) 0 NS
Otherd Benzodiazepines 39 (4.3) 2 (0.6) NS
ACE-inhibitors 14 (1.5) 1 (0.3) NS
Gabapentin 24 (2.6) 2 (0.6) NS
Levotiroxine 40 (4.4) 2 (0.6) NS
Tamsulosin 12 (1.3) 1 (0.3) NS
Baclofen 39 (4.3) 1 (0.3) NS
ACE: angiotensin-converting enzyme, CV: cardiovascular, NS: not significant, SNRI: serotonin norepinephrine reuptake inhibitor, SSRI: selective serotonin
reuptake inhibitor.
*P-value was calculated using the Fisher’s exact test.
aClomipramine and amitryptiline.
bCitalopram, escitalopram, fluoxetine, paroxetine, sertraline.
cDuloxetine and venlafaxine.
dIncludes all drugs taken by those who required prolonged monitoring excluded NSAIDs and acetaminophen.
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We report safety and tolerability data on the first ad-
ministration of fingolimod in a large cohort of Italian
patients resembling “real world” patients. In such a pa-
tient population, the first administration of fingolimod
was safe overall. Adverse events were reported for a
minority of patients (4.7%) and were of mild severity.
The only serious adverse event was one asymptomatic
case of AVB second degree Mobitz type I that required
hospitalization but resolved spontaneously. Only 2/906
patients discontinued the treatment at the first dose
administration due to an adverse event (asymptomatic
and spontaneously resolving AVB second degree, Mobitz
type 1, and mild persistent bradycardia). A total of 18/906
patients reported cardiac adverse events. A small number
of patients were not discharged after the first 6 hours, due
to AVB, symptomatic bradycardia, or lowest HR registeredat the sixth hour. It is important to underline that the
episodes of AVB and symptomatic bradycardia were
self-limiting and no patients developed life-threatening
changes in HR. In all three cases of AVB, the patients
had been previously treated with interferon; however,
given the duration of the washout period in each case,
and the short half-life of interferon (hours), we propose
it is unlikely that the previous interferon treatment
could have a synergistic role with fingolimod in causing
AVB. Although it would have interesting to be able to
analyse these data to further investigate the possible
predisposing or synergistic role of a previous disease-
modifying drug with fingolimod in causing AVB, the
variability in previous treatment regimens, duration and
washout periods, together with the limited number of
AVB cases did not allow a reliable statistical analysis to
be performed.
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development are often sufficient to delineate the benefit/
risk profile of a drug [11], the rate of rare adverse events
may be underestimated due to the limited number of
enrolled patients and to the particular selection criteria
employed [12,13]. From this point of view, controlled clin-
ical research has clear value in terms of intrinsic validity,
whereas high extrinsic validity is associated with large trials
or clinical experience in a real word setting. Patients in this
study were older, had higher disease duration and lower
mean relapse rate within the previous year in comparison
to the populations treated with the same dose of fingolimod
in phase III studies [1,3]. In these phase III studies, brady-
cardia was found in 0.9% and 0.5% of patients receiving fin-
golimod 0.5 mg/day, compared with 0.4% in the present
study. First degree AVB was found in 0.5% and 0.2% of pa-
tients in the phase 3 studies, while 0% and 0.2% of patients
demonstrated second degree AVB [1,3]. Table 5 compares
the occurrence of extended monitoring and cardiovascular
adverse events in this cohort to what was reported in a
pooled analysis of patients treated with the same dose of
fingolimod in phase III trials and from the US EPOC study
[6,14]. This comparison shows again that these frequencies
are consistent across the various studies, and confirms the
very benign cardiovascular profile of fingolimod both in
controlled clinical trials and in a real word experience like
this study.
About 1/3 of the large population included in this study
had other medical conditions and a significant number of
subjects (136/906, 15.0%) were treated with drugs that
may influence HR and conduction. Importantly, the use of
many medications which can cause bradycardia or influ-
ence the cardiac conduction, including beta-blockers or
anti-psychotic drugs, was not associated to cardiac adverse
events. Although we found some relationship between theTable 5 Clinical experience after one dose of fingolimod 0.5 m
comparison with a pooled analysis of three pivotal fingolimo
EPOC study [14]
n (%) CFTY720DIT03
n = 906
Discharged at 6 hours, did not return for monitoring 872 (96.2)
Required extended monitoring after 6 hours 34 (3.8)
5 required 2 days of
Required day 2 observation 10 (1.1)
Study drug discontinued 2 (0.2)
Symptomatic bradycardia 4 (0.4)
AVB, first degree 1b
AVB, second degree 2b
AVB: atrioventricular block.
aOnly patients treated with fingolimod 0.5 mg/day included.
bThe frequency of AVB was not calculated since ECG was not performed routinely i
not captured.use of topiramate, 4-aminopyridine and trazodone and the
need for extended monitoring, the patient numbers
were small and so firm conclusions cannot be drawn
from this result. While it appears that the impact of
existing cardiovascular-related medications on the ad-
verse event profile of fingolimod is small, further in-
vestigation into the effect of these drugs on the safety
and tolerability of fingolimod is warranted.
The strength of this study is the better generalizability
of its results, obtained in a large population of patients
resembling that of clinical practice in terms of concomi-
tant diseases and medications compared the selected
population of the pivotal phase III trials. Weaknesses
include the lack of a standardized definition of bradycar-
dia, and that ECG was performed only if clinically indi-
cated and not routinely. While this different procedure
may have led to missing some cardiovascular events,
especially in asymptomatic patients, we believe that the
likelihood of clinically relevant adverse events being
missed is small, considering that patients were continu-
ously followed for the first six hours through monitoring
HR, blood pressure and clinical status. In addition, it
should be considered that the clinical significance of
cardiovascular events following pharmacological stimula-
tion in patients with multiple sclerosis, who are otherwise
generally healthy (such as those enrolled in this study), is
different from that of patients with pre-existing cardiovas-
cular disease. In this context, the clinical relevance of
asymptomatic or mild symptomatic events, which may have
been missed during the first dose monitoring, is likely very
limited.
Conclusion
Taken together, the results of this study, run in a popula-
tion of patients with RRMS who did not have alternativeg/day in the present study (CFTY720DIT03) in
d phase III studies (2302, 2301, 2309 [6]) and the US
2302, 2301, 2309 [6] EPOC [14]
n = 1212a n = 783
1006 (83.0%) 772 (98.6%)
157 (12.9%) 10 (1.3%)
observation 2 required 2 days of observation
32 (2.6) 3 (0.4)
1 (0.1) 0 (0.0)
7 (0.6) 8 (1.0)
56 (4.7) 15b
2 (0.2) 0b
n all patients and the exact number of patients who underwent to ECG was
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clinical practice in terms of concomitant diseases and
medications, confirmed that the first dose administration
of fingolimod is generally safe and well tolerated.
Appendix 1
List of Local Ethical Committees:
Comitato Etico Dell’azienda Ospedaliera Universitaria
San Martino di Genova, Genoa Italy; Comitato Etico per
le Attività Biomediche Carlo Romano dell’Università
degli Studi Federico II di Napoli, Naples, Italy; Comitato
Etico dell’Università Sapienza, Rome, Italy; Comitato Etico
per le Province di Chieti e Pescara, Chieti, Italy; Comitato
Etico Area Vasta Centro, Azienda Ospedaliera Universitaria
Careggi di Firenze, Florence, Italy; Comitato Etico
dell’Ospedale San Raffaele, Milan, Italy; Comitato Etico
Interaziendale A. O. Citta’ della Salute e della Scienza
di Torino, Turin, Italy; Comitato Etico dell’Azienda
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